Prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up

Niels Adriaenssens,1 Beatrice Scholtes,2 Robin Bruyndonckx,3,4,5 Pauline Van Ngoc,2 Jan Yvan Jos Verbakel,6,7 An De Sutter,8 Stefan Heytens,6 Ann Van Den Brul,9 Isabelle Desombere,9 Pierre Van Damme,10 Herman Goossens,10 Laetitia Buret,2 Els Duysburgh,11 Samuel Coenen1,5

ABSTRACT
Objectives To estimate the prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers (PHCPs).
Design Prospective cohort study with 12 months of follow-up.
Setting Primary care in Belgium.
Participants Any general practitioner (GP) working in primary care in Belgium and any other PHCP from the same GP practice who physically manages (examines, tests, treats) patients were eligible. A convenience sample of 3648 eligible PHCPs from 2001 GP practices registered for this study (3044 and 604 to start in December 2020 and January 2021, respectively). 3390 PHCPs (92.9%) participated in their first testing time point (2820 and 565, respectively) and 2557 PHCPs (70.1%) in the last testing time point (December 2021).
Interventions Participants were asked to perform a rapid serological test targeting IgM and IgG against the receptor binding domain of SARS-CoV-2 and to complete an online questionnaire at each of maximum eight testing time points.
Primary and secondary outcome measures The prevalence, incidence and longevity of antibodies against SARS-CoV-2 both after natural infection and after vaccination.
Results Among all participants, 67% were women and 77% GPs. Median age was 43 years. The seroprevalence in December 2020 (before vaccination availability) was 15.1% (95% CI 13.5% to 16.6%), increased to 84.2% (95% CI 82.9% to 85.5%) in March 2021 (after vaccination availability) and reached 93.9% (95% CI 92.9% to 94.9%) in December 2021 (during booster vaccination availability and fourth (delta variant dominant) COVID-19 wave). Among not (yet) vaccinated participants the first monthly incidence of antibodies against SARS-CoV-2 was estimated to be 2.91% (95% CI 1.80% to 4.01%). The longevity of antibodies is higher in PHCPs with self-reported COVID-19 infection.

STRENGTHS AND LIMITATIONS OF THIS STUDY
⇒ Prospective cohort study with good response during 12 months of follow-up.
⇒ Rapid serological test (RST) measuring the presence of antibodies against SARS-CoV-2 after infection and vaccination, without distinction.
⇒ Timely and comparable estimates of the prevalence of antibodies against SARS-CoV-2 among primary healthcare providers.
⇒ Large sample size permitting precise estimates at national and regional level.
⇒ Convenience sample, missing data points and potentially lower actual RST accuracy limiting the study validity.

Conclusions This study confirms that occupational health measures provided sufficient protection when managing patients. High uptake of vaccination resulted in high seroprevalence of SARS-CoV-2 antibodies in PHCPs in Belgium. Longevity of antibodies was supported by booster vaccination and virus circulation.

Trial registration number NCT04779424.

INTRODUCTION
As of 8 June 2022, SARS-CoV-2 has caused over 530 million infections worldwide (4 164 698 in Belgium) and caused over 6.3 million deaths from coronavirus disease (COVID-19) worldwide (over 31 000 in Belgium).1 COVID-19 can be a lethal respiratory tract infection (RTI), but often presents with mild symptoms or remains asymptomatic.

Since the start of the COVID-19 pandemic, SARS-CoV-2 seroprevalence estimates have provided essential information about population exposure to infection and helped predict
the early course of the epidemic. When setting up this study, seroprevalence studies in Iceland and Spain showed different levels of population antibody positivity, lasting up to at least 4 months in Iceland. In addition, early cohort studies have suggested waning of antibody levels in individuals is associated with, for example, illness severity, age and comorbidities. Meanwhile, other seroprevalence studies showed antibody positivity lasting up to 9 months. Additionally, after vaccination, longevity of antibody positivity could differ depending on the type of vaccination and vaccination regime. For Belgium, Sciensano (the Belgian national institute of public health, www.sciensano.be) performs national seroprevalence studies of SARS-CoV-2 antibodies in the general population and several relevant populations including school-aged children and school staff, hospital staff, nursing homes residents and their staff. These results are publicly available and regularly updated on an online dashboard.

This article focuses on the seroprevalence among primary healthcare providers (PHCPs). PHCPs manage the vast majority of patient contacts, including COVID-19 patients, and therefore, play an essential role in the efficient organisation of healthcare. Among the PHCPs, general practitioners (GPs) in particular, act as gatekeepers to the next levels of care. Therefore, preserving the capacity of GPs, together with that of their coworkers, throughout the COVID-19 epidemic is essential. In Belgium, this is particularly concerning given that the GP workforce consists of mainly older adults and is therefore at higher risk for COVID-19-related morbidity and mortality. In Italy, GPs represented up to 38% of the physicians who died from COVID-19 early in the epidemic.

Before the start of this study (December 2020), data on how many PHCPs in Belgium had been infected by SARS-CoV-2 was not readily available, and effective vaccines for PHCPs were not anticipated to be available in the near future.

During the COVID-19 crisis rapid serological tests (RSTs) have been developed to identify the presence of antibodies to SARS-CoV-2. Compared with laboratory tests, a valid easy-to-use RST could speed up the availability of the test results for both the participants and the national health authorities. Furthermore, by using RSTs in this study, PHCPs got the opportunity to become more familiar with this type of technology.

Sciensano has validated five RSTs using finger prick blood, identifying one test with appropriate sensitivity (92.9%) and specificity (96.3%) for use in seroprevalence studies. We used this RST for this study. It targets IgM and IgG against the receptor binding domain (RBD) of SARS-CoV-2 and could therefore also provide valuable information in a vaccinated population.

Given the availability of vaccines for PHCPs soon after the start of this study, we now report on the prevalence of antibodies against SARS-CoV-2 among a cohort of PHCPs in Belgium followed-up for 12 months, and on the incidence and longevity of those antibodies both after natural infection and after vaccination.

METHODS
This study was a prospective cohort study. Data collection was performed according to the publicly available protocol, providing more details on the study methods.

Study population
Any GP working in Belgium (including those in professional training) working in primary care and any PHCP from the same GP practice in a clinical role (clinical examination, testing or treating patients) were eligible if they were able to comply with the study protocol and provided informed consent to participate in the study. Staff hired on a temporary (interim) basis were excluded as follow-up over time would be compromised. Administrative staff or technical staff without any prolonged (longer than 15 min) face-to-face contact with patients and PHCPs who were not professionally active during the inclusion period were not eligible either.

PHCPs were recruited between 15 November 2020 and 15 January 2021. GPs working in clinical practice in Belgium were invited to register online for participation in this national epidemiological study and were asked to invite the other PHCPs in their practice to do the same. We emphasised that PHCPs who had already been diagnosed with COVID-19 were also eligible. Information about the study was disseminated to GPs and PHCPs via professional organisations (Domus Medica and Collège de Médecine Générale), university networks across the country and through professional media channels. We checked our convenience sample for representativeness in terms of geographic and demographic characteristics.

To assess the geographical representativeness of our sample, we compared the distribution by region and by province of active GPs in Belgium in 2020 (source www.ima-aim.be) with the distribution of participating GPs.

Data collection
On inclusion in the study, participants were assigned a unique study code by the researchers and received testing material at their workplace through regular mail. At their first testing time point they received an invitation by email inviting them to autocollect a capillary blood sample and analyse it using the RST (OrientGene) and to complete a baseline questionnaire available in Dutch, French and English via a personalised link through a secured online platform hosted by Sciensano (Limesurvey). The invitation email included links to both written and video instructions to perform the RST on yourself and on someone else.

The baseline questionnaire at the first testing time point asked for written informed consent and for information about the result of the RST, basic sociodemographic data (age, gender, composition...
of household—eg, presence of school-aged children in the house), professional data (practice patient size), health status (pre-existing health conditions, regular medication use, presence of symptoms since the start of the epidemic, previous positive test results for COVID-19), professional exposure (contact with confirmed cases, use of infection prevention and control measures and the availability of personal protective equipment (PPE)) and practice organisational aspects (delayed care for non-urgent conditions) (see online supplemental file 1). A follow-up questionnaire was sent for each of the subsequent testing time points. In addition to the RST result, it collected information on the health status, including the presence of symptoms, COVID-19 testing and results, vaccination status (date of vaccination, type of vaccine, number of doses, presence of side effects) and professional exposure (contact with confirmed cases, use of infection prevention and control measures) (see online supplemental file 2).

Follow-up
The study lasted 12 months, from December 2020 to December 2021, and included eight testing time points. Compared with the study protocol, the testing time point at the fifth month was skipped because of limited additional epidemiological value based on progressive insights from studies with similar protocols conducted by Sciensano that longer interval than 4 weeks between testing time point are suitable.

Sample size
This study aimed to include 5000 PHCPs with a ratio of 4 GPs to 1 other PHCP. The sample size considerations regarding the different objectives of the proposed study are described in more detail in the study protocol. For the objectives reported here, even half the sample size aimed for would allow for precise estimates of the prevalence, incidence and longevity of antibodies against SARS-CoV-2.

Data analysis
In the analysis, we included all PHCPs who provided informed consent and reported RST results at the testing time points. If in the questionnaire the entry for the date the RST was performed was missing or implausible, the date of completing the questionnaire was used instead. All analyses were conducted using R V.4.1.0 (www.R-project.org).

Prevalence
To assess the prevalence of antibodies against SARS-CoV-2, we calculated among the valid RST the proportion (95% CI) of positive RST for IgG and/or IgM, and for IgG and IgM separately (crude seroprevalences). In addition, we calculated the proportion (95% CI) of PHCPs that self-reported testing positive for SARS-CoV-2 (no test specified, so this includes both virus or antibody detection) since the outbreak of the COVID-19 pandemic (February 2020) and the proportion (95% CI) of PHCPs with any positive test, either a positive study RST or testing positive since the outbreak at their first testing time point. For any subsequent testing time points, we asked the participants to specify if self-reported testing positive for SARS-CoV-2 since the previous testing time point concerned virus or antibody detection.

We also estimated the prevalence of antibodies against SARS-CoV-2 (IgG and/or IgM) taking into account clustering of PHCPs within their practice as well as the distribution of PHCPs across the districts in Belgium (adjusted seroprevalences). Weights were calculated based on the differences between the actual distribution of GPs across districts and the distribution of participating GPs with RST results across districts. These weights were then extrapolated to all other PHCPs. The estimates are based on generalised estimating equations assuming a binomial distribution for the RST result, an identity link function and an independent working correlation matrix. In a similar way, we also estimated the adjusted prevalence of self-reported positive testing for SARS-CoV-2 since the start of the COVID-19 pandemic and the adjusted prevalence of these two tests results combined, either a positive study RST or testing positive since the outbreak for the first two testing time points.

Incidence
To assess the incidence of antibodies against SARS-CoV-2 (IgG and/or IgM) among participants not (yet) vaccinated, we calculated the proportion of participants who reported positive testing for SARS-CoV-2 (IgG and/or IgM) due to vaccination in those not yet vaccinated, by analysing the data collected during the testing time points after the first testing time point. We included participants providing valid RST results both at the testing time point assessed and the preceding testing time point. We excluded participants reporting a positive RST at the preceding time point or already vaccinated with a first dose. In addition, we corrected the estimates for clustering of participants in general practices.

To assess the incidence of antibodies against SARS-CoV-2 (IgG and/or IgM) due to vaccination in those vaccinated, we calculated the proportion of participants with antibodies against SARS-CoV-2 less than 7 days and 7 days or more after the first, the second and the third dose of a COVID-19 vaccine, respectively, and stratified by self-reported history of COVID-19 infection.

Longevity
To assess the longevity of antibodies against SARS-CoV-2 (IgG and/or IgM) among participants not (yet) vaccinated, first we produced a Kaplan-Meier plot including participants providing a valid negative RST result at their first testing time point and not testing positive before, considering a positive RST during follow-up as event and censoring on vaccination or lost to follow-up. Second, we assessed the monthly incidence of antibodies against SARS-CoV-2 due to natural infection in those not yet vaccinated, by analysing the data collected during the testing time points after the first testing time point. We included participants providing valid RST results both at the testing time point assessed and the preceding testing time point. We excluded participants reporting a positive RST at the preceding time point or already vaccinated with a first dose. In addition, we corrected the estimates for clustering of participants in general practices.

Adriaenssens N, et al. BMJ Open 2022;12:e065897. doi:10.1136/bmjopen-2022-065897

Open access

Follow-up
The study lasted 12 months, from December 2020 to December 2021, and included eight testing time points. Compared with the study protocol, the testing time point at the fifth month was skipped because of limited additional epidemiological value based on progressive insights from studies with similar protocols conducted by Sciensano that longer interval than 4 weeks between testing time point are suitable.

Sample size
This study aimed to include 5000 PHCPs with a ratio of 4 GPs to 1 other PHCP. The sample size considerations regarding the different objectives of the proposed study are described in more detail in the study protocol. For the objectives reported here, even half the sample size aimed for would allow for precise estimates of the prevalence, incidence and longevity of antibodies against SARS-CoV-2.

Data analysis
In the analysis, we included all PHCPs who provided informed consent and reported RST results at the testing time points. If in the questionnaire the entry for the date the RST was performed was missing or implausible, the date of completing the questionnaire was used instead. All analyses were conducted using R V.4.1.0 (www.R-project.org).

Prevalence
To assess the prevalence of antibodies against SARS-CoV-2, we calculated among the valid RST the proportion (95% CI) of positive RST for IgG and/or IgM, and for IgG and IgM separately (crude seroprevalences). In addition, we calculated the proportion (95% CI) of PHCPs that self-reported testing positive for SARS-CoV-2 (no test specified, so this includes both virus or antibody detection) since the outbreak of the COVID-19 pandemic (February 2020) and the proportion (95% CI) of PHCPs with any positive test, either a positive study RST or testing positive since the outbreak at their first testing time point. For any subsequent testing time points, we asked the participants to specify if self-reported testing positive for SARS-CoV-2 since the previous testing time point concerned virus or antibody detection.

We also estimated the prevalence of antibodies against SARS-CoV-2 (IgG and/or IgM) taking into account clustering of PHCPs within their practice as well as the distribution of PHCPs across the districts in Belgium (adjusted seroprevalences). Weights were calculated based on the differences between the actual distribution of GPs across districts and the distribution of participating GPs with RST results across districts. These weights were then extrapolated to all other PHCPs. The estimates are based on generalised estimating equations assuming a binomial distribution for the RST result, an identity link function and an independent working correlation matrix. In a similar way, we also estimated the adjusted prevalence of self-reported positive testing for SARS-CoV-2 since the start of the COVID-19 pandemic and the adjusted prevalence of these two tests results combined, either a positive study RST or testing positive since the outbreak for the first two testing time points.

Incidence
To assess the incidence of antibodies against SARS-CoV-2 (IgG and/or IgM) among participants not (yet) vaccinated, we calculated the proportion of participants who reported positive testing for SARS-CoV-2 (IgG and/or IgM) due to vaccination in those not yet vaccinated, by analysing the data collected during the testing time points after the first testing time point. We included participants providing valid RST results both at the testing time point assessed and the preceding testing time point. We excluded participants reporting a positive RST at the preceding time point or already vaccinated with a first dose. In addition, we corrected the estimates for clustering of participants in general practices.

To assess the incidence of antibodies against SARS-CoV-2 (IgG and/or IgM) due to vaccination in those vaccinated, we calculated the proportion of participants with antibodies against SARS-CoV-2 less than 7 days and 7 days or more after the first, the second and the third dose of a COVID-19 vaccine, respectively, and stratified by self-reported history of COVID-19 infection.

Longevity
To assess the longevity of antibodies against SARS-CoV-2 (IgG and/or IgM) among participants not (yet) vaccinated, first we produced a Kaplan-Meier plot including participants providing a valid negative RST result at their first testing time point and not testing positive before, considering a positive RST during follow-up as event and censoring on vaccination or lost to follow-up. Second, we assessed the monthly incidence of antibodies against SARS-CoV-2 due to natural infection in those not yet vaccinated, by analysing the data collected during the testing time points after the first testing time point. We included participants providing valid RST results both at the testing time point assessed and the preceding testing time point. We excluded participants reporting a positive RST at the preceding time point or already vaccinated with a first dose. In addition, we corrected the estimates for clustering of participants in general practices.

To assess the incidence of antibodies against SARS-CoV-2 (IgG and/or IgM) due to vaccination in those vaccinated, we calculated the proportion of participants with antibodies against SARS-CoV-2 less than 7 days and 7 days or more after the first, the second and the third dose of a COVID-19 vaccine, respectively, and stratified by self-reported history of COVID-19 infection.

Adriaenssens N, et al. BMJ Open 2022;12:e065897. doi:10.1136/bmjopen-2022-065897

Open access
participants without a self-reported history of COVID-19 infection before their first testing time point that provided a valid positive RST results before receiving their first dose of a COVID-19 vaccine, considering a negative RST result during follow-up as event (= negative RST result followed by another negative RST result or missing data) and censoring on vaccination or lost to follow-up (midpoint and interval censoring). Second, we included participants not yet vaccinated, that provided a valid RST result at the testing time point assessed and a positive RST result at the previous testing time point. We estimated the proportion with a negative test result at the testing time point assessed.

To assess the longevity of antibodies against SARS-CoV-2 (IgG and/or IgM) after COVID-19 vaccination, we produced Kaplan-Meier plots by self-reported history of COVID-19 infection, including participants that provided a valid positive RST results at least 7 days after receiving their second dose of a COVID-19 vaccine, considering a negative RST result during follow-up as event (= negative RST result followed by another negative RST result or missing data) and censoring on booster vaccination (date of third dose) or lost to follow-up (midpoint and interval censoring).

Vaccination

The start of the vaccination of PHCPs during the study follow-up provided the opportunity to monitor its progress.

Patient and public involvement

Neither patients (or PHCPs in this specific study) nor the public were involved in the design of the study. During the study, the information shown in figure 1 was shared with the participants and the general population through the publicly available website of the Belgian health authorities (Sciensano) shortly after each testing—time point both for Belgium and its three regions, Brussels, Flanders and Wallonia.18

RESULTS

Description of the study cohort

In total, 3648 eligible PHCPs from 2001 practices registered and were asked to provide informed consent of whom 3044 and 604 PHCPs were sent personal study materials to be able to collect data for their first testing time point starting on 24 December 2020 and 25 January 2021, respectively. A total of 3390 PHCPs participated in their first testing time point by completing the baseline questionnaire, among which 2597 GPs, 386 GPs in training and 407 other PHCPs (table 1).

Our sampling procedure resulted in the participation of a reasonably geographically representative sample of GPs at the level of the provinces (online supplemental table S1). At the level of the regions, there is about 8% overrepresentation of GPs in Flanders and corresponding underrepresentation of GPs in Wallonia.

Participant characteristics

Table 1 presents the characteristics of the 3390 PHCPs who participated in their first (baseline) testing time point. These PHCPs, mainly GPs, were relatively young, more often female and working more often in (large) group practices than in solo or duo practices. Table 2 shows in how many testing time points PHCPs participated. A total of 3415 (93.6%) PHCPs participated in at least one testing time point, 2909 (79.7%) participated in 6 and 2141 (58.7%) participated in all 8 testing time points. The number of PHCPs participating per testing time point is presented in online supplemental table S2. While the response rate gradually decreased, still 2557 (77.2% of invited PHCPs) participated in the last testing time point.

Vaccination status

Overall, 3227 participants received a full primary vaccination. 2783 participants received two doses of an mRNA vaccine (2639 (81.8%) BNT162b2, 144 (4.5%) mRNA-1273 and 2 (0.1%) mRNA-1273 followed by BNT162b2). A total of 437 participants (13.5%) received two doses of
ChAdOx1-S and 5 (0.2%) participants one dose of Ad26.COV2.S.

At the final testing time point, 2211 of the participants had received a booster vaccination. A total of 1879 (85.0%) participants received a booster with BNT162b2 and 267 (12.1%) with mRNA-1273. 1 participant received ChAdOx1-S and another participant Ad26.COV2.S as third dose.

Prevalence

The prevalence of antibodies against SARS-CoV-2 among PHCPs in Belgium from December 2020 to December 2021 is shown in figure 1 and online supplemental table S3. Online supplemental table S3 also gives the number of eligible PHCPs, that is, those testing between the start and end date of the respective testing time point, as well as the regional differences. At the first testing time point (T1), among 2680 eligible PHCPs, 2629 provided valid test results, of which 366 (15.1%) were positive. Afterwards, the prevalence increased substantially up to 84.2% at T4, mainly due to vaccination (see online supplemental table S4). Six months later (T7) the prevalence was substantially lower (70.2%), while during the fourth COVID-19 wave (delta variant dominant) and after booster vaccination became available it increased again to 93.9% (T8).

Incidence

Among not (yet) vaccinated participants

The incidence of antibodies against SARS-CoV-2 among PHCPs in Belgium among participants that provided a valid negative RST result at their first testing time point, did not self-report a COVID-19 infection before and were not (yet) vaccinated is shown in figure 2. For the second testing time point (T2), the monthly incidence of antibodies against SARS-CoV-2 was estimated to be 2.91% (95% CI 1.80% to 4.01%; n=895), that is, the proportion of PHCPs not yet vaccinated at T2 and testing negative at T1, that tested positive at T2. For T3 and T4, it was estimated to be 3.93% (95% CI 2.04% to 5.82%; n=407) and 4.04% (95% CI 0.16% to 7.92%; n=99), respectively. As of T4, the sample size of eligible participants was too small for precise estimates.

Among vaccinated participants

The incidence of antibodies against SARS-CoV-2 among vaccinated PHCPs in Belgium according to their self-reported history of COVID-19 infection is shown in figure 3. The incidence of antibodies is higher in PHCPs with self-reported COVID-19 infection compared with PHCPs with no self-reported COVID-19 infection both less than 7 days and 7 days or more after the first and the

Table 1  Characteristics of primary healthcare providers (PHCPs), including general practitioners (GPs), GPs in training and other PHCPs who participated in their first testing time points*

|                       | PHCPs n=3390 | GPs n=2597 | GPs in training n=386 | Other PHCPs n=407 |
|-----------------------|--------------|------------|-----------------------|-------------------|
| Age†, median (IQR)    | 40 (31-54)   | 44 (34-57) | 27 (26-28)            | 38 (31-47)        |
| Gender‡, n (%)        |              |            |                       |                   |
| Male                  | 1119 (33.0)  | 943 (36.3) | 112 (29.0)            | 64 (15.7)         |
| Female                | 2296 (66.9)  | 1652 (63.6)| 274 (71.0)            | 343 (84.3)        |
| Not reported          | 2 (0.1)      | 2 (0.1)    | 0 (0)                 | 0 (0)             |
| Practice size, n (%)‡|              |            |                       |                   |
| Solo                  | 618 (33.5)   | 580 (34.7) | 54 (16.1)             | 29 (11.8)         |
| Duo                   | 361 (19.6)   | 328 (19.6) | 74 (22.1)             | 32 (13.1)         |
| Group (<8 employees)  | 382 (20.7)   | 351 (21.0) | 51 (15.2)             | 21 (8.6)          |
| Large group (>7 employees) | 444 (24.1)  | 386 (23.1) | 156 (46.6)            | 150 (61.2)        |

*The first testing time point was December 2020 for 2820 and January 2021 for 570 PHCPs, respectively.
†Ages <21 were considered unrealistic and recoded as missing; IQR=IQR range.
‡If numbers do not add up to the column total, this is due to missing data; numbers of practices for PHCPs=1845, GPs=1672, GPs in training=335 and other PHCPs=245.

Table 2  The number of testing time points that primary healthcare providers (PHCPs) participated in

| No of testing time points participated in | No of PHCPs (%) | Cumulative percentage |
|------------------------------------------|-----------------|-----------------------|
| 8*                                       | 2141 (58.7)     | 58.7                  |
| 7                                        | 490 (13.4)      | 72.1                  |
| 6                                        | 278 (7.6)       | 79.7                  |
| 5                                        | 153 (4.2)       | 83.9                  |
| 4                                        | 129 (3.5)       | 87.5                  |
| 3                                        | 91 (2.5)        | 90.0                  |
| 2                                        | 87 (2.4)        | 92.4                  |
| 1                                        | 46 (1.3)        | 93.6                  |
| 0                                        | 233 (6.4)       | 100.0                 |

*The eight testing time points have the following start and end dates: T1: 24 December 2021–8 January 2021, T2: 25 January 2021–31 January 2021, T3: 22 February 2021–28 February 2021, T4: 22 March 2021–31 March 2021, T5: 19 April 2021–28 April 2021, T6: 14 June 2021–27 June 2021, T7, 13 September 2021–2 September 2021, T8: 13 December–26 December 2021.
second dose, less than 7 days after the third dose, but not 7 days or more after the third dose.

**Longevity**

**Among not (yet) vaccinated participants**

The longevity of antibodies against SARS-CoV-2 among not (yet) vaccinated PHCPs in Belgium is shown in figure 4.

For T2 the positivity of antibodies against SARS-CoV-2 was estimated to be 18.54% (95% CI 12.84% to 24.24%; n=178)) lower compared with T1, that is, the proportion of participants not yet vaccinated at T1 and testing positive at T1 for SARS-CoV-2 antibodies that tested negative for SARS-CoV-2 antibodies at T2. For T3 and T4 it was estimated to be 19.42% (95% CI 11.76% to 27.07%; n=103) and 12.50% (95% CI 0.99% to 24.01%; n=32), respectively. As of T4, the sample size of eligible participants was too small for precise estimates.

**Among participants after full primary vaccination**

The longevity of antibodies against SARS-CoV-2 among PHCPs in Belgium who have received their full primary vaccination, but not yet a booster vaccination, according to their self-reported history of COVID-19 infection is shown in figure 5. The longevity of antibodies is higher in PHCPs with self-reported COVID-19 infection compared with PHCPs without self-reported COVID-19 infection after full primary vaccination.

---

**Figure 2** Kaplan-Meier plot of incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium not yet vaccinated after self-reported COVID-19 infection. Interval censoring is taken into account by assuming that the actual event occurred somewhere between the testing time point of the event and the testing time point before.

**Figure 4** Kaplan-Meier plot of longevity of antibodies against SARS-CoV-2 among PHCPs in Belgium after self-reported history of COVID-19 infection. Interval censoring is taken into account by assuming that the actual event occurred somewhere between the testing time point of the event and the testing time point before.

**Figure 3** Incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium after vaccination according to self-reported history of COVID-19 infection.
DISCUSSION
The prevalence of antibodies against SARS-CoV-2 among PHCPs in Belgium was 15.1% in December 2020, that is, before vaccination had started and right after the second Belgian COVID-19 wave that peaked beginning November 2020, and reached 93.9% in December 2021, i.e. after booster vaccination had started and after the fourth Belgian COVID-19 wave in which the Delta variant was dominant and that peaked beginning December 2021. The incidence of antibodies against SARS-CoV-2 within 2 weeks after COVID-19 vaccination with a first dose was higher in PHCPs with a self-reported history of COVID-19 infection compared with those with no self-reported history of infection. The longevity of antibodies was more pronounced in the former group of PHCPs than in those with no self-reported history of infection.

The seroprevalence in PHCPs before vaccination (15.1%) appeared to be lower than that among the general population (18.7%) and that among hospital healthcare workers (19.7%) in Belgium, in December 2020, when the Belgian healthcare system was approaching the end of the second COVID-19 wave. It should, however, be noted that the accuracy of the RST might be lower when used by many different PHCPs instead of a few trained and experienced staff (for validation) and lower than analysis of a serum sample in the lab (for seroprevalence in the general population and in hospital healthcare workers) using conventional lab-tests. This is suggested by the lower seroprevalence in this study for PHCPs in Flanders compared with that in an earlier prospective cohort study using dried blood spots (DBS) analysed in the lab. Not finding a higher seroprevalence among PHCPs, generally concerned about being at high risk of COVID-19 infections, compared with the general population might be explained by the availability and proper usage of PPE.

Most PHCPs in our study (94.49%) received a first vaccine dose in the period January–March explaining the increase in seroprevalence to 84.1% in April 2021. The monthly incidence of antibodies due to natural infection in those not yet vaccinated in the same time period was estimated to be around 4% in this study. Natural course of infection could, therefore, not have caused a similar rise in seroprevalence.

A gradual decrease in the prevalence of anti-SARS-CoV-2 antibodies among PHCP was observed in the following months leading to a seroprevalence of 70.2% in September 2021. In December 2021 most PHCPs (86.5% of participants in testing time point 8) already received a booster dose of a COVID-19 vaccine resulting in a seroprevalence of 93.1% at the end of the study. Although, also the circulation of Delta variant corona virus might have impacted this increase in seroprevalence. For example, the seroprevalence in mainly unvaccinated schoolchildren in Belgium almost doubled during the fourth COVID-19 wave (26.6% at 8 October 2021 vs 50.9% at 15 December 2021). Natural infection before vaccination did seem to limit waning of antibodies after vaccination. These findings strengthen the accruing evidence base for reduced protection from infection in vaccinated, but previously uninfected participants. The clinical significance is however still to be determined. A reduction in vaccine effectiveness against infection could increase transmission to and the risk of infection among high-risk persons who consult PHCPs, some of whom may have progression to severe disease. In addition, recent studies have shown that vaccination confers more durable protection against severe outcomes of hospitalisation and death than against mild symptomatic and asymptomatic infection.

At this point, studies suggest that a third or booster dose provides additional protection on top of simply reversing previous waning, but that the greatest protection from
the worst clinical outcomes still remains heavily concentrated in the first two doses.32–36

Although studies suggest prolonged protection, it remains unclear to what extent the presence of antibodies (against the RBD) is associated with protection against new variants of the coronavirus.36,37 Neutralising antibody titers measured in the laboratory remain the strongest correlate of protection against symptomatic and severe illness across multiple variants.38,39

This large cohort study with 12 months follow-up provided precise estimates of the prevalence and incidence of antibodies against SARS-CoV-2 among PHCPs at national and regional level. Another strength of this study is the use of RSTs. This substantially improved the timeliness of the test result availability and allowed the PHCPs to immediately check their results, which was not the case in our previous work that used DBS to assess the prevalence and incidence of antibodies against SARS-CoV-2 among PHCPs in Flanders.23 Consequently, the results in PHCPs in Belgium could be compared much faster to that of the general population and other population groups, for example, healthcare workers in hospitals and nursing homes.

In addition, the RST used in this study allowed us to estimate the incidence and longevity of antibodies against SARS-CoV-2 both after natural infection and after vaccination. This, on the other hand, also limits seroprevalence studies like ours and others,16 using an RST not able to distinguish antibodies after natural infection (with new variants) from antibodies after vaccination, to assess virus circulation once the target population is highly vaccinated.

Lost to follow-up or missing data, reduced accuracy of the RST in primary care and the use of a convenience sample could also have limited the validity of the study results. However, overall retention and response of PHCPs in the study was good to excellent, we used the best available RST to avoid under- and overestimation of the presence of SARS-CoV-2 among PHCPs due to imperfect testing methods (imperfect sensitivity and specificity), and the estimates were corrected for clustering and potential geographical misrepresentation of the PHCPs. Still, the RST used is less accurate than the ELISA and missing this reference test’s quantitative aspect.

Selection bias is possible, because the study started at the end of the second COVID-19 wave: if all the most vulnerable PHCPs had already been infected at the time of the start of this study, then the incidence among the remaining PHCPs may be lower (because better immune system, more adherent to personal protection guidelines, etc.). Therefore, we explicitly asked for participation regardless of previous SARS-CoV-2 testing and test results.

In conclusion, this national study confirms results from an earlier study at regional level (Flanders only) that for the PHCPs seroprevalence and incidence during the second COVID-19 wave was similar to that of the general population suggesting that the occupational health measures implemented provided sufficient protection when managing patients. A vaccination programme including one booster increased the seroprevalence of antibodies against SARS-CoV-2 leading to a seroprevalence of 93.9% in December 2021. Between primary and booster vaccination, longevity of antibodies was more pronounced in PHCPs with a history of self-reported COVID-19 infection. Therefore, continued monitoring of the seroprevalence in PHCPs after booster vaccination, with longer time intervals, could be relevant, provided that the presence of antibodies is associated with protection.

Author affiliations
1Family Medicine & Population Health, Centre for General Practice, University of Antwerp Faculty of Medicine and Health Sciences, Antwerp (Wilrijk), Belgium
2General Practice Department, Primary Care and Health Research Unit, Liege University, Liege, Belgium
3Interuniversity Institute for Biostatistics and statistical Bioinformatics (I-BIOSTAT), Hasselt University, Hasselt, Limburg, Belgium
4Epidemiology & Pharmacovigilance, P95, Leuven, Belgium
5Vaccine & Infectious Disease Institute, Laboratory of Medical Microbiology, University of Antwerp, Antwerp (Wilrijk), Belgium
6Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
7Department of Public Health and Primary Care, KU Leuven, Leuven, Flanders, Belgium
8Department of Public Health and Primary Care, Ghent University, Gent, Belgium
9Department of Infectious Diseases in Humans, Sciensano, Brussels, Belgium
10Vaccine & Infectious Disease Institute, Centre for the Evaluation of Vaccination, University of Antwerp Faculty of Medicine and Health Sciences, Antwerp (Wilrijk), Belgium
11Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium

Twitter Jan Yvan Jos Verbakel @jan_verbakel

Contributors The study concept and design was initiated by SC, NA, BS and ED and finalised with contributions from JYJV, ADS, SH, AVDB, ID, PVD, HG, SC, NA, BS and PVN conducted registration and data collection. Analysis was performed by RB. NA prepared the first draft of the manuscript. All authors (NA, BS, RB, PVN, JYJV, ADS, SH, AVDB, ID, PVD, HG, SC, NA) provided edits and critically approved the manuscript for intellectual content, approved the submitted version, were involved in the interpretation of data, and agree to be accountable for all aspects of the work. NA and BS contributed equally to this work as first author. ED and SC contributed equally to this work as last author. SC is acting as guarantor.

Funding ‘This work was supported by Sciensano, grant number (OZ8478)’. JYJV was further supported by the National Institute for Health and Care Research (NIHR) Community Healthcare MedTech and In Vitro Diagnostics Co-operative at Oxford Health NHS Foundation Trust.

Disclaimer The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

Competing interests None declared.

Patient and public involvement Patients and/or the public were involved in the design, conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Not applicable.

Ethics approval Ethical approval granted at 16 November 2020 (reference number: 20/46/605) by the Ethics Committee of the University Hospital Antwerp/University of Antwerp (Belgian registration number: 3002020000237). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. The relevant anonymised patient-level data as well as statistical code that support the findings of this study are available from the corresponding author on reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been
peer-reviewed. Any options or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Niels Adriaenssens http://orcid.org/0000-0002-7957-1177
Beatrice Scholtes http://orcid.org/0000-0001-5274-822X
Robin Bruynodcnckx http://orcid.org/0000-0002-4217-2869
Pauline Van Ngoc http://orcid.org/0000-0003-0925-9994
Jan Van Jos Verbakel http://orcid.org/0000-0002-7166-7211
An De Sutter http://orcid.org/0000-0002-2540-8307
Stefan Heytens http://orcid.org/0000-0003-1097-4987
Ann Van Den Bruel http://orcid.org/0000-0001-9012-2009
Laetitia Buret http://orcid.org/0000-0002-3511-7712
Herman Goossens http://orcid.org/0000-0003-4891-4031
Els Daysburgh http://orcid.org/0000-0003-3435-7616
Niels Adriaenssens http://orcid.org/0000-0002-7957-1177

REFERENCES
1 WHO. WHO coronavirus (COVID-19) Dashboard. Available: https://covid19.who.int [Accessed 9 Jun 2022].
2 Altor G, Seder R. The power of antibody-based surveillance. N Engl J Med 2020;383:1782–4.
3 Koopmans M, Haagmans B. Assessing the extent of SARS-CoV-2 circulation through serological studies. Nat Med 2020;26:1171–2.
4 Guirdjikian DF, Norddahl GL, Melsted P, et al. Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med 2020;383:1724–34.
5 Poliani M, Pérez-Corneto B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet 2020;396:535–44.
6 Patel MM, Thornburg NJ, Stubblefield WB, et al. Change in antibodies to SARS-CoV-2 over 60 days among health care personnel in Nashville, Tennessee. JAMA 2020;324:1781–2.
7 Long Q-X, Tang X-J, Shi Q-L, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 2020;26:1200–12.
8 Ibarrao FJ, Fulcher JA, Goodman-Meza D, et al. Rapid decay of Anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med 2020;383:1085–7.
9 Yao L, Wang G-L, Shen Y, et al. Persistence of antibody and cellular immune responses in coronavirus disease 2019 patients over nine months after infection. J Infect Dis 2021;224:586–94.
10 Duyssburgh E, Mortgat L, Barbazon G, et al. Persistence of lgG response to SARS-CoV-2. Lancet Infect Dis 2021;21:163–4.
11 Barouch DH, Stephenson KE, Sadoff J, et al. Durable humoral and cellular immune responses 8 months after Ad26.COV2.S vaccination. N Engl J Med 2021;385:951–3.
12 Favresse J, Bayart J-L, Muller F, et al. Antibody titres decline 3-month post-vaccination with BNT162b2. Emerg Microbes Infect 2021;10:1495–6.
13 Leclercq V, Van den Houte N, Gisle L, et al. Prevalence of Anti-SARS-CoV-2 antibodies and potential determinants among the Belgian adult population: baseline results of a prospective cohort study. Viruses 2022;14:920.
14 Merckx J, Veermeulen M, Vandermeulen C. Prevalence and incidence of antibodies against SARS-CoV-2 in children and school staff measured for one year in Belgium: a sero-epidemiological prospective cohort study. Available: https://www.sciensano.be/nl/biblio/prevalence-and-incidence-antibodies-against-sars-cov-2-children-and-school-staff-measured-one-year [Accessed 9 Jun 2022].